03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
23:30 , Mar 13, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of PHLDA1 could help predict resistance to RTK inhibitors in endometrial, breast and other cancers. In tumor samples from patients with metastatic breast cancer or locally advanced non-metastatic renal cancer...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DNA (cytosine-5-)-methyltransferase 1 (DNMT1)

Cancer INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting DNMT1 could help treat pancreatic ductal adenocarcinoma (PDAC). In patient tumor samples, levels of DNMT1 mRNA were higher in cancer stem cells...
07:00 , Jul 2, 2012 |  BioCentury  |  Emerging Company Profile

Activiomics: Unlabeled proteomics

Most proteomics platforms that rely on labeling can only be used in cell lines and handle a small number of samples in any one experiment, making it difficult to quantify significant changes in cell signaling....
07:00 , Jun 16, 2011 |  BC Innovations  |  Targets & Mechanisms

Meet the METs

Researchers at Queen Mary, University of London have found that blocking endocytosis could treat MET-mutant cancers resistant to current treatments. 1 Developing a safe way to inhibit the essential cellular process could prove challenging. Endocytosis...